Shares of NeurAxis, Inc. (NASDAQ:NRXS – Get Free Report) rose 1.6% on Monday . The stock traded as high as $7.07 and last traded at $6.86. 20,185 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 141,502 shares. The stock had previously closed at $6.75.
NeurAxis Trading Down 2.0%
The firm has a fifty day simple moving average of $7.12 and a 200-day simple moving average of $6.45. The stock has a market cap of $85.08 million, a price-to-earnings ratio of -3.73 and a beta of 1.43.
Hedge Funds Weigh In On NeurAxis
Large investors have recently made changes to their positions in the company. Money Concepts Capital Corp boosted its holdings in NeurAxis by 566.6% in the fourth quarter. Money Concepts Capital Corp now owns 222,605 shares of the company’s stock valued at $1,011,000 after acquiring an additional 189,210 shares during the last quarter. Rosalind Advisors Inc. bought a new stake in NeurAxis during the 4th quarter worth about $1,299,000. Geode Capital Management LLC raised its holdings in NeurAxis by 48.8% during the 4th quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock worth $343,000 after purchasing an additional 24,817 shares during the last quarter. State Street Corp acquired a new position in NeurAxis during the 4th quarter valued at about $139,000. Finally, Manatuck Hill Partners LLC acquired a new position in NeurAxis during the 2nd quarter valued at about $122,000. Institutional investors and hedge funds own 11.77% of the company’s stock.
NeurAxis Company Profile
NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.
NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.
Featured Stories
- Five stocks we like better than NeurAxis
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
